OSBPL3 and Patent ductus arteriosus: Moreover, increased OSBPL3 expression impacted on the malignant behaviors of PDA, <i>e.g.</i>, reduced PDA cell sensitivity to oxaliplatin, whereas inhibition of NOTCH pathway significantly attenuated the drug resistance and stemness features induced by increased OSBPL3 expression, suggesting that OSBPL3 modulated PDA malignancy via oncogenic pathways such as NOTCH signaling pathway.